GREY:ICOTF - Post by User
Post by
eddy0505on Jun 24, 2018 6:02am
95 Views
Post# 28219892
Trials & milestone payments
Trials & milestone payments 
Bertilimumab
Bertilimumab is a first-in-class human monoclonal antibody designed to block the protein eotaxin-1, which is responsible for causing inflammation in a significant number of diseases. Eotaxin-1 causes eosinophils to migrate toward sites of inflammation, where they release substances that damage tissue and enhance inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils, thus helping to relieve inflammatory conditions associated with the protein. Bertilimumab is currently in phase 2 clinical trials for bullous pemphigoid, an orphan auto-immune skin blistering disease, and ulcerative colitis. Bertilimumab was initially developed by Cambridge Antibody Technology (now part of MedImmune, the biologics division of AstraZeneca), licensed by Immune in June 2011, while iCo Therapeutics retains the rights to develop any ophthalmic indications.
antibody targeting eotaxin-1. Partners: AstraZeneca MedImmune & Immune Pharmaceuticals ... $7,000,000 USD in milestone payments. • Worldwide (WW) exclusive rights. Out-licensed systemic uses to. Immune ...